Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases (505 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013 Sep 13; 8(9): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference,
Impact factor: 3.534, 5-year impact factor: 4.015
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84884132303&partnerID=40&md5=434f79a1b7515fbeacb8d1f6eba44719
Keywords: [cysteinyltryptophanylhistidylarginylcysteine], Arginylalanine [cysteinylarginyltyrosyltryptophanylcysteine], Arginylalanine[cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine[cysteinylarginylphenylalanylphenylalanylcysteine], Chemokine Receptor Cxcr4, Cyclopeptide, Mitogen Activated Protein Kinase 1, Plerixafor, Unclassified Drug, Amino Acid Sequence, Animal Cell, Animal Experiment, Animal Model, Article, Calcium Transport, Cancer Cell, Cancer Inhibition, Cell Migration, Controlled Study, Drug Activity, Drug Design, Enzyme Induction, Female, Human, Human Cell, In Vitro Study, In Vivo Study, Kidney Cancer, Lung Metastasis, Melanoma B16, Melanoma Cell, Metastasis Inhibition, Mouse, Nonhuman, Osteosarcoma Cell, Receptor Binding, Tumor Xenograft, Wound Healing, Cell Line, Cell Movement, Cell Proliferation, Chemokine Cxcl12, Drug Screening Assays, Antitumor, Extracellular Signal-Regulated Map Kinases, Lung Neoplasms, Inbred Balb C, Inbred C57bl, Molecular Sequence Data, Phosphorylation, Protein Binding, Arginylalanine [cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine [cysteinylarginylphenylalanylphenylalanylcysteine],
Affiliations:
*** IBB - CNR ***
Department of Oncological Immunology, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
Animal Facility, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
ICB-CNR, CNR, Pozzuoli, Italy
IBB-CNR, CNR, Naples, Italy
CROM, Mercogliano (AV), Italy
Azienda Sanitaria Locale n 5 Spezzino, La Spezia, Italy
References:
Baggiolini, M., Chemokines in pathology and medicine (2001) J Intern Med, 250, pp. 91-10
Allen, S.J., Crown, S.E., Handel, T.M., Chemokine: receptor structure, interactions, and antagonism (2007) Annu Rev Immunol, 25, pp. 787-820
Wu, X., Lee, V.C., Chevalier, E., Hwang, S.T., Chemokine receptors as targets for cancer therapy (2009) Curr Pharm Des 2009, 15, pp. 742-757
Teicher, B.A., Fricker, S.P., CXCL12 (SDF-1)/CXCR4 pathway in cancer (2010) Clin Cancer Res, 16, pp. 2927-2931
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Involvement of chemokine receptors in breast cancer metastasis (2001) Nature, 410, pp. 50-56
Balabanian, K., Lagane, B., Infantino, S., Chow, K.Y., Harriague, J., The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes (2005) J Biol Chem, 280, pp. 35760-35766
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., Lagane, B., CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling (2009) Blood, 113, pp. 6085-6093
Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D., CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? (2011) Clin Cancer Res, 17, pp. 2074-2080
Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Control of chemokine-guided cell migration by ligand sequestration (2008) Cell, 132, pp. 463-473
Zabel, B.A., Wang, Y., Lewen, S., Berahovich, R.D., Penfold, M.E., Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands (2009) J Immunol, 183, pp. 3204-3211
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 (1996) Nature, 382, pp. 635-638
Sierro, F., Biben, C., Martinez-Munoz, L., Mellado, M., Ransohoff, R.M., Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 (2007) Proc Natl Acad Sci U S A, 104, pp. 14759-14764
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract (1998) Nature, 393, pp. 591-594
Scala, S., Ottaiano, A., Ascierto, P.A., Cavalli, M., Simeone, E., Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma (2005) Clin Cancer Res 2005, 11, pp. 1835-1841
Scotton, C.J., Wilson, J.L., Scott, K., Stamp, G., Wilbanks, G.D., Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer (2002) Cancer Res, 62, pp. 5930-5938
Ottaiano, A., Franco, R., Aiello Talamanca, A., Liguori, G., Tatangelo, F., Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients (2006) Clin Cancer Res, 12, pp. 2795-2803
Tavor, S., Petit, I., Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? (2010) Semin Cancer Biol, 20, pp. 178-185
Kioi, M., Vogel, H., Schultz, G., Hoffman, R.M., Harsh, G.R., Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice (2010) J Clin Invest, 120, pp. 694-705
Kozin, S.V., Kamoun, W.S., Huang, Y., Dawson, M.R., Jain, R.K., Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation (2010) Cancer Res, 70, pp. 5679-5685
D'Alterio, C., Barbieri, A., Portella, L., Palma, G., Polimeno, M., Inhibition of stromal CXCR4 impairs development of lung metastases (2012) Cancer Immunol Immunother, 61 (10), pp. 1713-1720
Hiratsuka, S., Duda, D.G., Huang, Y., Goel, S., Sugiyama, T., C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells (2011) Proc Natl Acad Sci U S A, 108, pp. 302-307
Vose, J.M., Ho, A.D., Coiffier, B., Corradini, P., Khouri, I., Advances in mobilization for the optimization of autologous stem cell transplantation (2009) Leuk Lymphoma, 50, pp. 1412-1421
De Clercq, E., The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil) (2009) Biochem Pharmacol, 77, pp. 1655-1664
Hendrix, C.W., Collier, A.C., Lederman, M.M., Schols, D., Pollard, R.B., Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection (2004) J Acquir Immune Defic Syndr, 37, pp. 1253-1262
Clark-Lewis, I., Kim, K.S., Rajarathnam, K., Gong, J.H., Dewald, B., Structure-activity relationships of chemokines (1995) J Leukoc Biol, 57, pp. 703-711
Baggiolini, M., Dewald, B., Moser, B., Human chemokines: an update (1997) Annu Rev Immunol, 15, pp. 675-705
Crump, M.P., Gong, J.H., Loetscher, P., Rajarathnam, K., Amara, A., Solution structure and basis for functional activity of stromal cell-derived factor-1
dissociation of CXCR4 activation from binding and inhibition of HIV-1 (1997) EMBO J, 16, pp. 6996-7007
Kledal, T.N., Rosenkilde, M.M., Coulin, F., Simmons, G., Johnsen, A.H., A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus (1997) Science, 277, pp. 1656-1659
Shan, L., Qiao, X., Oldham, E., Catron, D., Kaminski, H., Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1 (2000) Biochem Biophys Res Commun, 268, pp. 938-941
Crump, M.P., Elisseeva, E., Gong, J., Clark-Lewis, I., Sykes, B.D., Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10) (2001) FEBS Lett, 489, pp. 171-175
Booth, V., Slupsky, C.M., Clark-Lewis, I., Sykes, B.D., Unmasking ligand binding motifs: identification of a chemokine receptor motif by NMR studies of antagonist peptides (2003) J Mol Biol, 327, pp. 329-334
Amodeo, P., Vitale, R.M., De Luca, S., Scala, S., Castello, G., (2010) Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses, , Italian patent: no. MI2010A 000093
international patent n° WO2011/092575 A
Fricker, S.P., Anastassov, V., Cox, J., Darkes, M.C., Grujic, O., Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 (2006) Biochem Pharmacol 2006, 72, pp. 588-596
Scala, S., Giuliano, P., Ascierto, P.A., Ieranò, C., Franco, R., Human melanoma metastases express functional CXCR4 (2006) Clin Cancer Res, 12, pp. 2427-2433
Murakami, T., Maki, W., Cardones, A.R., Fang, H., Tun Kyi, A., Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells (2002) Cancer Res, 62, pp. 7328-7334
Richert, M.M., Vaidya, K.S., Mills, C.N., Wong, D., Korz, W., Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone (2009) Oncol Rep, 21, pp. 761-767
Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., CXCR4 regulates growth of both primary and metastatic breast cancer (2004) Cancer Res, 64, pp. 8604-8612
Gravel, S., Malouf, C., Boulais, P.E., Berchiche, Y.A., Oishi, S., The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains (2010) J Biol Chem, 285, pp. 37939-37943
Rettig, M.P., Ansstas, G., DiPersio, J.F., Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 (2012) Leukemia, 26, pp. 34-53
Masuda, M., Nakashima, H., Ueda, T., Naba, H., Ikoma, R., A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II) (1992) Biochem Biophys Res Commun, 189, pp. 845-850
Beider, K., Begin, M., Abraham, M., Wald, H., Weiss, I.D., CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth (2011) Exp Hematol, 39, pp. 282-292
Tamamura, H., Hori, A., Kanzaki, N., Hiramatsu, K., Mizumoto, M., T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer (2003) FEBS Lett, 550, pp. 79-83
Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer (2004) Mol Cancer Ther, 3, pp. 29-37
Abraham, M., Biyder, K., Begin, M., Wald, H., Weiss, I.D., Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003 (2007) Stem Cells, 25, pp. 2158-2166
Porvasnik, S., Sakamoto, N., Kusmartsev, S., Eruslanov, E., Kim, W.J., Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth (2009) Prostate, 69, pp. 1460-1469
Kwong, J., Kulbe, H., Wong, D., Chakravarty, P., Balkwill, F., An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells (2009) Mol Cancer Ther, 8, pp. 1893-1905
Xu, L., Duda, D.G., di Tomaso, E., Ancukiewicz, M., Chung, D.C., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
Rao, S., Sengupta, R., Choe, E.J., Woerner, B.M., Jackson, E., CXCL12 mediates trophic interactions between endothelial and tumor cells (2012) PLoS One, 7 (3), pp. e3305
Allen, S. J., Crown, S. E., Handel, T. M., Chemokine: receptor structure, interactions, and antagonism (2007) Annu Rev Immunol, 25, pp. 787-820
Wu, X., Lee, V. C., Chevalier, E., Hwang, S. T., Chemokine receptors as targets for cancer therapy (2009) Curr Pharm Des 2009, 15, pp. 742-757
Teicher, B. A., Fricker, S. P., CXCL12 (SDF-1) /CXCR4 pathway in cancer (2010) Clin Cancer Res, 16, pp. 2927-2931
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., CXCL12 (SDF1alpha) -CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? (2011) Clin Cancer Res, 17, pp. 2074-2080
Zabel, B. A., Wang, Y., Lewen, S., Berahovich, R. D., Penfold, M. E., Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands (2009) J Immunol, 183, pp. 3204-3211
Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer (2002) Cancer Res, 62, pp. 5930-5938
Kozin, S. V., Kamoun, W. S., Huang, Y., Dawson, M. R., Jain, R. K., Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation (2010) Cancer Res, 70, pp. 5679-5685
Vose, J. M., Ho, A. D., Coiffier, B., Corradini, P., Khouri, I., Advances in mobilization for the optimization of autologous stem cell transplantation (2009) Leuk Lymphoma, 50, pp. 1412-1421
Hendrix, C. W., Collier, A. C., Lederman, M. M., Schols, D., Pollard, R. B., Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection (2004) J Acquir Immune Defic Syndr, 37, pp. 1253-1262
Crump, M. P., Gong, J. H., Loetscher, P., Rajarathnam, K., Amara, A., Solution structure and basis for functional activity of stromal cell-derived factor-1
Kledal, T. N., Rosenkilde, M. M., Coulin, F., Simmons, G., Johnsen, A. H., A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus (1997) Science, 277, pp. 1656-1659
Crump, M. P., Elisseeva, E., Gong, J., Clark-Lewis, I., Sykes, B. D., Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10) (2001) FEBS Lett, 489, pp. 171-175
Fricker, S. P., Anastassov, V., Cox, J., Darkes, M. C., Grujic, O., Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 (2006) Biochem Pharmacol 2006, 72, pp. 588-596
Richert, M. M., Vaidya, K. S., Mills, C. N., Wong, D., Korz, W., Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone (2009) Oncol Rep, 21, pp. 761-767
Smith, M. C., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., CXCR4 regulates growth of both primary and metastatic breast cancer (2004) Cancer Res, 64, pp. 8604-8612
Rettig, M. P., Ansstas, G., DiPersio, J. F., Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 (2012) Leukemia, 26, pp. 34-53
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013 Sep 13; 8(9): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference,
Impact factor: 3.534, 5-year impact factor: 4.015
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84884132303&partnerID=40&md5=434f79a1b7515fbeacb8d1f6eba44719
Keywords: [cysteinyltryptophanylhistidylarginylcysteine], Arginylalanine [cysteinylarginyltyrosyltryptophanylcysteine], Arginylalanine[cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine[cysteinylarginylphenylalanylphenylalanylcysteine], Chemokine Receptor Cxcr4, Cyclopeptide, Mitogen Activated Protein Kinase 1, Plerixafor, Unclassified Drug, Amino Acid Sequence, Animal Cell, Animal Experiment, Animal Model, Article, Calcium Transport, Cancer Cell, Cancer Inhibition, Cell Migration, Controlled Study, Drug Activity, Drug Design, Enzyme Induction, Female, Human, Human Cell, In Vitro Study, In Vivo Study, Kidney Cancer, Lung Metastasis, Melanoma B16, Melanoma Cell, Metastasis Inhibition, Mouse, Nonhuman, Osteosarcoma Cell, Receptor Binding, Tumor Xenograft, Wound Healing, Cell Line, Cell Movement, Cell Proliferation, Chemokine Cxcl12, Drug Screening Assays, Antitumor, Extracellular Signal-Regulated Map Kinases, Lung Neoplasms, Inbred Balb C, Inbred C57bl, Molecular Sequence Data, Phosphorylation, Protein Binding, Arginylalanine [cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine [cysteinylarginylphenylalanylphenylalanylcysteine],
Affiliations:
*** IBB - CNR ***
Department of Oncological Immunology, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
Animal Facility, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
ICB-CNR, CNR, Pozzuoli, Italy
IBB-CNR, CNR, Naples, Italy
CROM, Mercogliano (AV), Italy
Azienda Sanitaria Locale n 5 Spezzino, La Spezia, Italy
References:
Baggiolini, M., Chemokines in pathology and medicine (2001) J Intern Med, 250, pp. 91-10
Allen, S.J., Crown, S.E., Handel, T.M., Chemokine: receptor structure, interactions, and antagonism (2007) Annu Rev Immunol, 25, pp. 787-820
Wu, X., Lee, V.C., Chevalier, E., Hwang, S.T., Chemokine receptors as targets for cancer therapy (2009) Curr Pharm Des 2009, 15, pp. 742-757
Teicher, B.A., Fricker, S.P., CXCL12 (SDF-1)/CXCR4 pathway in cancer (2010) Clin Cancer Res, 16, pp. 2927-2931
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Involvement of chemokine receptors in breast cancer metastasis (2001) Nature, 410, pp. 50-56
Balabanian, K., Lagane, B., Infantino, S., Chow, K.Y., Harriague, J., The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes (2005) J Biol Chem, 280, pp. 35760-35766
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., Lagane, B., CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling (2009) Blood, 113, pp. 6085-6093
Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D., CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? (2011) Clin Cancer Res, 17, pp. 2074-2080
Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Control of chemokine-guided cell migration by ligand sequestration (2008) Cell, 132, pp. 463-473
Zabel, B.A., Wang, Y., Lewen, S., Berahovich, R.D., Penfold, M.E., Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands (2009) J Immunol, 183, pp. 3204-3211
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 (1996) Nature, 382, pp. 635-638
Sierro, F., Biben, C., Martinez-Munoz, L., Mellado, M., Ransohoff, R.M., Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 (2007) Proc Natl Acad Sci U S A, 104, pp. 14759-14764
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract (1998) Nature, 393, pp. 591-594
Scala, S., Ottaiano, A., Ascierto, P.A., Cavalli, M., Simeone, E., Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma (2005) Clin Cancer Res 2005, 11, pp. 1835-1841
Scotton, C.J., Wilson, J.L., Scott, K., Stamp, G., Wilbanks, G.D., Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer (2002) Cancer Res, 62, pp. 5930-5938
Ottaiano, A., Franco, R., Aiello Talamanca, A., Liguori, G., Tatangelo, F., Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients (2006) Clin Cancer Res, 12, pp. 2795-2803
Tavor, S., Petit, I., Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? (2010) Semin Cancer Biol, 20, pp. 178-185
Kioi, M., Vogel, H., Schultz, G., Hoffman, R.M., Harsh, G.R., Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice (2010) J Clin Invest, 120, pp. 694-705
Kozin, S.V., Kamoun, W.S., Huang, Y., Dawson, M.R., Jain, R.K., Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation (2010) Cancer Res, 70, pp. 5679-5685
D'Alterio, C., Barbieri, A., Portella, L., Palma, G., Polimeno, M., Inhibition of stromal CXCR4 impairs development of lung metastases (2012) Cancer Immunol Immunother, 61 (10), pp. 1713-1720
Hiratsuka, S., Duda, D.G., Huang, Y., Goel, S., Sugiyama, T., C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells (2011) Proc Natl Acad Sci U S A, 108, pp. 302-307
Vose, J.M., Ho, A.D., Coiffier, B., Corradini, P., Khouri, I., Advances in mobilization for the optimization of autologous stem cell transplantation (2009) Leuk Lymphoma, 50, pp. 1412-1421
De Clercq, E., The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil) (2009) Biochem Pharmacol, 77, pp. 1655-1664
Hendrix, C.W., Collier, A.C., Lederman, M.M., Schols, D., Pollard, R.B., Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection (2004) J Acquir Immune Defic Syndr, 37, pp. 1253-1262
Clark-Lewis, I., Kim, K.S., Rajarathnam, K., Gong, J.H., Dewald, B., Structure-activity relationships of chemokines (1995) J Leukoc Biol, 57, pp. 703-711
Baggiolini, M., Dewald, B., Moser, B., Human chemokines: an update (1997) Annu Rev Immunol, 15, pp. 675-705
Crump, M.P., Gong, J.H., Loetscher, P., Rajarathnam, K., Amara, A., Solution structure and basis for functional activity of stromal cell-derived factor-1
dissociation of CXCR4 activation from binding and inhibition of HIV-1 (1997) EMBO J, 16, pp. 6996-7007
Kledal, T.N., Rosenkilde, M.M., Coulin, F., Simmons, G., Johnsen, A.H., A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus (1997) Science, 277, pp. 1656-1659
Shan, L., Qiao, X., Oldham, E., Catron, D., Kaminski, H., Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1 (2000) Biochem Biophys Res Commun, 268, pp. 938-941
Crump, M.P., Elisseeva, E., Gong, J., Clark-Lewis, I., Sykes, B.D., Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10) (2001) FEBS Lett, 489, pp. 171-175
Booth, V., Slupsky, C.M., Clark-Lewis, I., Sykes, B.D., Unmasking ligand binding motifs: identification of a chemokine receptor motif by NMR studies of antagonist peptides (2003) J Mol Biol, 327, pp. 329-334
Amodeo, P., Vitale, R.M., De Luca, S., Scala, S., Castello, G., (2010) Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses, , Italian patent: no. MI2010A 000093
international patent n° WO2011/092575 A
Fricker, S.P., Anastassov, V., Cox, J., Darkes, M.C., Grujic, O., Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 (2006) Biochem Pharmacol 2006, 72, pp. 588-596
Scala, S., Giuliano, P., Ascierto, P.A., Ieranò, C., Franco, R., Human melanoma metastases express functional CXCR4 (2006) Clin Cancer Res, 12, pp. 2427-2433
Murakami, T., Maki, W., Cardones, A.R., Fang, H., Tun Kyi, A., Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells (2002) Cancer Res, 62, pp. 7328-7334
Richert, M.M., Vaidya, K.S., Mills, C.N., Wong, D., Korz, W., Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone (2009) Oncol Rep, 21, pp. 761-767
Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., CXCR4 regulates growth of both primary and metastatic breast cancer (2004) Cancer Res, 64, pp. 8604-8612
Gravel, S., Malouf, C., Boulais, P.E., Berchiche, Y.A., Oishi, S., The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains (2010) J Biol Chem, 285, pp. 37939-37943
Rettig, M.P., Ansstas, G., DiPersio, J.F., Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 (2012) Leukemia, 26, pp. 34-53
Masuda, M., Nakashima, H., Ueda, T., Naba, H., Ikoma, R., A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II) (1992) Biochem Biophys Res Commun, 189, pp. 845-850
Beider, K., Begin, M., Abraham, M., Wald, H., Weiss, I.D., CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth (2011) Exp Hematol, 39, pp. 282-292
Tamamura, H., Hori, A., Kanzaki, N., Hiramatsu, K., Mizumoto, M., T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer (2003) FEBS Lett, 550, pp. 79-83
Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer (2004) Mol Cancer Ther, 3, pp. 29-37
Abraham, M., Biyder, K., Begin, M., Wald, H., Weiss, I.D., Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003 (2007) Stem Cells, 25, pp. 2158-2166
Porvasnik, S., Sakamoto, N., Kusmartsev, S., Eruslanov, E., Kim, W.J., Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth (2009) Prostate, 69, pp. 1460-1469
Kwong, J., Kulbe, H., Wong, D., Chakravarty, P., Balkwill, F., An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells (2009) Mol Cancer Ther, 8, pp. 1893-1905
Xu, L., Duda, D.G., di Tomaso, E., Ancukiewicz, M., Chung, D.C., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
Rao, S., Sengupta, R., Choe, E.J., Woerner, B.M., Jackson, E., CXCL12 mediates trophic interactions between endothelial and tumor cells (2012) PLoS One, 7 (3), pp. e3305
Allen, S. J., Crown, S. E., Handel, T. M., Chemokine: receptor structure, interactions, and antagonism (2007) Annu Rev Immunol, 25, pp. 787-820
Wu, X., Lee, V. C., Chevalier, E., Hwang, S. T., Chemokine receptors as targets for cancer therapy (2009) Curr Pharm Des 2009, 15, pp. 742-757
Teicher, B. A., Fricker, S. P., CXCL12 (SDF-1) /CXCR4 pathway in cancer (2010) Clin Cancer Res, 16, pp. 2927-2931
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., CXCL12 (SDF1alpha) -CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? (2011) Clin Cancer Res, 17, pp. 2074-2080
Zabel, B. A., Wang, Y., Lewen, S., Berahovich, R. D., Penfold, M. E., Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands (2009) J Immunol, 183, pp. 3204-3211
Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer (2002) Cancer Res, 62, pp. 5930-5938
Kozin, S. V., Kamoun, W. S., Huang, Y., Dawson, M. R., Jain, R. K., Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation (2010) Cancer Res, 70, pp. 5679-5685
Vose, J. M., Ho, A. D., Coiffier, B., Corradini, P., Khouri, I., Advances in mobilization for the optimization of autologous stem cell transplantation (2009) Leuk Lymphoma, 50, pp. 1412-1421
Hendrix, C. W., Collier, A. C., Lederman, M. M., Schols, D., Pollard, R. B., Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection (2004) J Acquir Immune Defic Syndr, 37, pp. 1253-1262
Crump, M. P., Gong, J. H., Loetscher, P., Rajarathnam, K., Amara, A., Solution structure and basis for functional activity of stromal cell-derived factor-1
Kledal, T. N., Rosenkilde, M. M., Coulin, F., Simmons, G., Johnsen, A. H., A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus (1997) Science, 277, pp. 1656-1659
Crump, M. P., Elisseeva, E., Gong, J., Clark-Lewis, I., Sykes, B. D., Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10) (2001) FEBS Lett, 489, pp. 171-175
Fricker, S. P., Anastassov, V., Cox, J., Darkes, M. C., Grujic, O., Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 (2006) Biochem Pharmacol 2006, 72, pp. 588-596
Richert, M. M., Vaidya, K. S., Mills, C. N., Wong, D., Korz, W., Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone (2009) Oncol Rep, 21, pp. 761-767
Smith, M. C., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., CXCR4 regulates growth of both primary and metastatic breast cancer (2004) Cancer Res, 64, pp. 8604-8612
Rettig, M. P., Ansstas, G., DiPersio, J. F., Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 (2012) Leukemia, 26, pp. 34-53
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer (2009) Cancer Res, 69, pp. 7905-7910
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.
The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
No results. |
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
Other filter: ([btitle,keywords] "[cysteinyltryptophan ...
Pelagalli A, Nardelli A, Lucarelli E, Zannetti A, Brunetti A
* Autocrine signals increase Ovine Mesenchymal Stem Cells migration through Aquaporin-1 and CXCR4 overexpression (723 views)
J Cell Physiol (ISSN: 1097-4652electronic, 0021-9541linking), 2018 Jan 18; 233(8): 6241-6249.
Impact Factor: 5.546
View Export to BibTeX Export to EndNote
Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A
* Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells (1108 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2018; 61(7): 2910-2923.
Impact Factor: 5.207
View Export to BibTeX Export to EndNote
Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (931 views) (PDF 283 views)
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 7.36
View Export to BibTeX Export to EndNote
Calce E, Vitale RM, Scaloni A, Amodeo P, De Luca S
* Air oxidation method employed for the disulfide bond formation of natural and synthetic peptides (604 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2015; 47(8): 1507-1515.
Impact Factor: 3.196
View Export to BibTeX Export to EndNote
Vincenzi M, Costantini S, Scala S, Tesauro D, Accardo A, Leone M, Colonna G, Guillon J, Portella L, Trotta AM, Ronga L, Rossi F
* Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4 (604 views)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(6): 12159-12173.
Impact Factor: 3.257
View Export to BibTeX Export to EndNote
Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S
* CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not (671 views)
Cell Mol Immunol (ISSN: 1672-7681), 2014 Nov 3; 12(4): 474-482.
Impact Factor: 4.112
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (441 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R, Faiella M, Maglio O, Pavone V
* Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity (596 views)
Faseb J (ISSN: 0892-6638, 0892-6638linking), 2011 Apr; 25(4): 1230-1243.
Impact Factor: 5.712
View Export to BibTeX Export to EndNote
Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
* CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients (403 views)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.
Impact Factor: 4.293
View Export to BibTeX Export to EndNote
Ierano C, Giuliano P, D'Alterio C, Cioffi M, Mettivier V, Portella L, Napolitano M, Barbieri A, Arra C, Liguori G, Franco R, Palmieri G, Rozzo C, Pacelli R, Castello G, Scala S
* A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration (394 views)
Cell Cycle (ISSN: 1538-4101), 2009 Apr 15; 8(8): 1228-1237.
Impact Factor: 4.087
View Export to BibTeX Export to EndNote
Palladino P, Tizzano B, Pedone C, Ragone R, Rossi F, Saviano G, Tancredi T, Benedetti E
* Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1α N-terminus (378 views)
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 2005 Oct 10; 579(24): 5293-5298.
Impact Factor: 3.415
View Export to BibTeX Export to EndNote
Palladino P, Pedone C, Ragone R, Rossi F, Saviano M, Benedetti E
* A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor (351 views)
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2003 Apr; 10(2): 133-138.
Impact Factor: 0.46
View Export to BibTeX Export to EndNote
Palladino P, De Capua A, Pedone C, Ragone R, Rossi F, Limatola C, Ragozzino D, Benedetti E
* A simplified model of the interaction between SDF-1 chemokine and the CXCR4 receptor (384 views)
Peptide Revolution, 2003 Apr; 10(2): 133-138.
Impact Factor: 4.659
View Export to BibTeX Export to EndNote
* Autocrine signals increase Ovine Mesenchymal Stem Cells migration through Aquaporin-1 and CXCR4 overexpression (723 views)
J Cell Physiol (ISSN: 1097-4652electronic, 0021-9541linking), 2018 Jan 18; 233(8): 6241-6249.
Impact Factor: 5.546
View Export to BibTeX Export to EndNote
Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A
* Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells (1108 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2018; 61(7): 2910-2923.
Impact Factor: 5.207
View Export to BibTeX Export to EndNote
Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (931 views) (PDF 283 views)
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 7.36
View Export to BibTeX Export to EndNote
Calce E, Vitale RM, Scaloni A, Amodeo P, De Luca S
* Air oxidation method employed for the disulfide bond formation of natural and synthetic peptides (604 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2015; 47(8): 1507-1515.
Impact Factor: 3.196
View Export to BibTeX Export to EndNote
Vincenzi M, Costantini S, Scala S, Tesauro D, Accardo A, Leone M, Colonna G, Guillon J, Portella L, Trotta AM, Ronga L, Rossi F
* Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4 (604 views)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(6): 12159-12173.
Impact Factor: 3.257
View Export to BibTeX Export to EndNote
Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S
* CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not (671 views)
Cell Mol Immunol (ISSN: 1672-7681), 2014 Nov 3; 12(4): 474-482.
Impact Factor: 4.112
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (441 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R, Faiella M, Maglio O, Pavone V
* Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity (596 views)
Faseb J (ISSN: 0892-6638, 0892-6638linking), 2011 Apr; 25(4): 1230-1243.
Impact Factor: 5.712
View Export to BibTeX Export to EndNote
Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
* CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients (403 views)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.
Impact Factor: 4.293
View Export to BibTeX Export to EndNote
Ierano C, Giuliano P, D'Alterio C, Cioffi M, Mettivier V, Portella L, Napolitano M, Barbieri A, Arra C, Liguori G, Franco R, Palmieri G, Rozzo C, Pacelli R, Castello G, Scala S
* A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration (394 views)
Cell Cycle (ISSN: 1538-4101), 2009 Apr 15; 8(8): 1228-1237.
Impact Factor: 4.087
View Export to BibTeX Export to EndNote
Palladino P, Tizzano B, Pedone C, Ragone R, Rossi F, Saviano G, Tancredi T, Benedetti E
* Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1α N-terminus (378 views)
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 2005 Oct 10; 579(24): 5293-5298.
Impact Factor: 3.415
View Export to BibTeX Export to EndNote
Palladino P, Pedone C, Ragone R, Rossi F, Saviano M, Benedetti E
* A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor (351 views)
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2003 Apr; 10(2): 133-138.
Impact Factor: 0.46
View Export to BibTeX Export to EndNote
Palladino P, De Capua A, Pedone C, Ragone R, Rossi F, Limatola C, Ragozzino D, Benedetti E
* A simplified model of the interaction between SDF-1 chemokine and the CXCR4 receptor (384 views)
Peptide Revolution, 2003 Apr; 10(2): 133-138.
Impact Factor: 4.659
View Export to BibTeX Export to EndNote
13 Records (13 excluding Abstracts).
Total impact factor: 56.389 (56.389 excluding Abstracts).
Total 5 year impact factor: 50.003 (50.003 excluding Abstracts).
Total impact factor: 56.389 (56.389 excluding Abstracts).
Total 5 year impact factor: 50.003 (50.003 excluding Abstracts).
505 views. Last view on Friday 19 May 2023, 17:43:02
ibb.cnr.it
